Public Release: 

Genes and drugs team up to lower blood pressure

BioMed Central

Patients with high blood pressure respond very differently to antihypertensive medication, making treatment selection tricky for physicians. But new research published in the online open access journal, BMC Medical Genetics, pinpoints a number of gene-drug interactions that could allow medication to be tailored to individual patients based on their genetics.

Sharon Kardia from the University of Michigan together with a US team drawn from the University of Texas, Houston and the Mayo Clinic, Rochester, studied siblings with hypertension participating in a Genetic Epidemiology Network of Arteriopathy study. The team took blood pressure readings and details of the subjects' drug regimens. Using these data, the authors found a new set of single nucleotide polymorphisms (SNPs) on the adducin 2 (ADD2) gene that may influence the regulation of blood pressure among people with hypertension.

Variation in blood pressure was affected by genotype, drugs and interactions between the two. The researchers used cross-validation methods to test the predictive power of their findings on individuals outside the study group, eliminating false positive findings.

Three SNPs were associated with differential blood pressure responses in beta-blocker users versus diuretic users while two other SNPs were associated with differential responses in renin-angiotensin-aldosterone system (RAAS) inhibitor users versus diuretic users. The findings also provide initial evidence that the effects of genetic variation on blood pressure in people with untreated hypertension may be very different compared with those taking medication. Although the authors looked at individual SNPs, it is also likely that SNPs interact.

"We suspected that ADD2 could be associated with differences in response to different antihypertensives because adducins have been proposed to regulate renal tubular transport of Na+ reabsorption and the development of hypertension," says Kardia.

Today's drugs target the body's systems for regulating blood pressure, so understanding individuals' differing responses to hypertensive drugs based on genetic and environmental factors is particularly worthwhile to create tailored drug regimens. Prospective studies with individuals selected based on their genotype, along with further SNP investigations, are the next steps toward translating these findings into clinical practice.

###

Article:

Interactions between the adducin 2 gene and antihypertensive drug therapies in determining blood pressure in people with hypertension Sharon L.R. Kardia, Yan V. Sun, Sara C. Hamon, Ruth Ann Barkley, Eric Boerwinkle, Stephen T. Turner
BMC Medical Genetics (in press)

During the embargo, article available at:
http://www.biomedcentral.com/imedia/1705253050134144_article.pdf?random=953559

After the embargo, article available from the journal website at:
http://www.biomedcentral.com/bmcmedgenet/

Article citation and URL available on request at press@biomedcentral.com on the day of publication

For author contact details, please contact:

Charlotte Webber on +44 (0)20 7631 9980 or press@biomedcentral.com
Lauren Hillman on +001 202.898.2000 (ext. 117) or Lauren.Hillman@fusionpr.com

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.